Assess prevalence and correlates of cannabis use in adults with attention-deficit/hyperactivity disorder (ADHD) and explore its impact on comorbidities, symptoms, and side effects of prescription stimulants.
Methods:
An anonymous online survey (April to July 2023) was emailed to 9,274 potential adult participants with a documented ADHD diagnosis, based on ICD-10 codes in the electronic medical record, which was secondarily verified by self-report. A total of 900 participants completed the survey. The 46-item survey covered demographics, medical history, prescription stimulant use, cannabis use, and its impact on ADHD symptoms and prescribed stimulant side effects, prescription stimulant misuse, cannabis use disorder, and health-related quality of life.
Results:
In this large sample of adults diagnosed with ADHD, 75% reported ever using cannabis, with 41% reporting prior 30-day use. Groups of cannabis users were categorized into three groups; (1) no recent use (including never; N = 458); (2) non-daily use (<30 days in past month; N = 256); and (3) daily use (≥30 days in past month; N = 112). Compared to non-daily cannabis users, daily cannabis users showed comparable rates of prescription stimulant misuse (29% vs. 37%, OR = 1.39, 95% CI [0.87, 2.23], p = .166), and substance use disorder diagnoses (2% vs. 4%, OR = 1.54, 95% CI [0.43, 5.58], p = .508), but higher rates of cannabis use disorder (38% vs. 62%, OR = 2.67, 95% CI [1.69, 4.22], p < .001). Daily cannabis users were more likely to report fair or poor general health compared to non-daily cannabis users (24% vs. 11%, OR = 2.58, 95% CI [1.44, 4.64], p = .001). Daily cannabis users were more likely to report a comorbid diagnosis of anxiety (70% vs. 48%, OR = 2.55, 95% CI [1.59, 4.10], p < .001), depression (54% vs. 35%, OR = 2.24, 95% CI [1.42, 3.53], p < .001), bipolar disorder (15% vs. 5%, OR = 3.345, 95% CI [1.56, 7.15], p = .002), and post-traumatic stress disorder (PTSD) (30% vs. 14%, OR = 2.752, 95% CI [1.61, 4.71], p < .001), compared to non-daily cannabis users. Among participants who ever used cannabis, 278 (42%) reported they had used cannabis to manage their ADHD symptoms. Compared to non-daily cannabis users, daily cannabis users were significantly more likely to report that cannabis use improved ADHD symptoms of mental frustration (OR = 2.39, 95% CI [1.36, 4.19], p = .002) and impulsivity (OR = 1.69, 95% CI [1.07, 2.69], p = .026). Daily cannabis users were more likely to report that cannabis use worsened ADHD symptoms of inattention (OR = .59, 95% CI [0.36, 0.98], p = .043) compared to non-daily cannabis users. Participants reported mixed effects of cannabis use on anxiety: 156 noted improvements, while 34 reported worsening.
Conclusion:
In this sample of adults diagnosed with ADHD, cannabis use was prevalent, with daily users showing higher rates of cannabis use disorder and co-morbid psychiatric diagnoses compared to non-daily users, highlighting the need for clinicians to screen for cannabis use disorder and psychiatric comorbidities. Cannabis users reported mixed effects of cannabis on ADHD symptoms and anxiety. Further research is warranted to understand the complex relationship between cannabis use, ADHD symptoms, and mental health.
AdlerL. A.SpencerT.BrownT. E.HoldnackJ.SaylorK.SchuhK.TrzepaczP. T.WilliamsD. W.KelseyD. (2009). Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: A 6-month, double-blind trial. Journal of Clinical Psychopharmacology, 29(1), 44–50.
2.
AdlerL. A.SpencerT. J.MiltonD. R.MooreR. J.MichelsonD. (2005). Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: An interim analysis. Journal of Clinical Psychiatry, 66(3), 294–299.
3.
AsselinA.LamarreO. B.ChamberlandR.McNeilS.-J.DemersE.ZongoA. (2022). A description of self-medication with cannabis among adults with legal access to cannabis in Quebec, Canada. Journal of Cannabis Research, 4(1), 26.
4.
BiedermanJ.SpencerT. J.WilensT. E.WeislerR. H.ReadS. C.TullochS. J. (2005). Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD. CNS Spectrums, 10(S20), 16–25.
5.
BlancoC.HasinD. S.WallM. M.Flórez-SalamancaL.HoertelN.WangS.KerridgeB. T.OlfsonM. (2016). Cannabis use and risk of psychiatric disorders: Prospective evidence from a US national longitudinal study. JAMA Psychiatry, 73(4), 388–395. https://doi.org/10.1001/jamapsychiatry.2015.3229
6.
Bonn-MillerM. O.BodenM. T.BucossiM. M.BabsonK. A. (2014). Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users. American Journal of Drug and Alcohol Abuse, 40(1), 23–30. https://doi.org/10.3109/00952990.2013.821477
7.
Bonn-MillerM. O.HeinzA. J.SmithE. V.BrunoR.AdamsonS. (2016). Preliminary development of a brief cannabis use disorder screening tool: The cannabis use disorder identification test short-form. Cannabis and Cannabinoid Research, 1(1), 252–261.
8.
BroydS. J.van HellH. H.BealeC.YücelM.SolowijN. (2016, Apr1). Acute and chronic effects of cannabinoids on human cognition-a systematic review. Biological Psychiatry, 79(7), 557–567. https://doi.org/10.1016/j.biopsych.2015.12.002
9.
BurgardT.BošnjakM.WedderhoffN. (2020). Response rates in online surveys with affective disorder participants. Zeitschrift für Psychologie. 28(1), 14–24.
10.
CalloviniT.JaniriD.SegatoriD.MastroeniG.KotzalidisG. D.Di NicolaM.SaniG. (2024). Examining the myth of prescribed stimulant misuse among individuals with attention-deficit/hyperactivity disorder: A systematic review. Pharmaceuticals, 17(8), 1076. https://www.mdpi.com/1424-8247/17/8/1076
11.
Center for Disease Control and Prevention. (1998). Self-reported frequent mental distress among adults–United States, 1993-1996. MMWR. Morbidity and Mortality Weekly Report, 47(16), 326–331.
ChaiG.GovernaleL.McMahonA. W.TrinidadJ. P.StaffaJ.MurphyD. (2012). Trends of outpatient prescription drug utilization in US children, 2002-2010. Pediatrics, 130(1), 23–31. https://doi.org/10.1542/peds.2011-2879
14.
ChildressA.SibleyM.SolantoM. V.WiznitzerM.NewcornJ. H. (2023). Guidelines in the United States for the diagnosis and treatment of attention-deficit/hyperactivity disorder in adults: Why they are needed. Psychiatric Annals, 53(10), 461–469.
15.
ChoiS.HuangB. C.GamaldoC. E. (2020). Therapeutic uses of cannabis on sleep disorders and related conditions. Journal of Clinical Neurophysiology, 37(1), 39–49.
16.
ChoiW. S.WooY. S.WangS. M.LimH. K.BahkW. M. (2022). The prevalence of psychiatric comorbidities in adult ADHD compared with non-ADHD populations: A systematic literature review. PloS One, 17(11), e0277175. https://doi.org/10.1371/journal.pone.0277175
17.
ComptonW. M.HanB.BlancoC.JohnsonK.JonesC. M. (2018). Prevalence and correlates of prescription stimulant use, misuse, use disorders, and motivations for misuse among adults in the United States. American Journal of Psychiatry, 175(8), 741–755.
18.
ComptonW. M.HanB.JonesC. M.BlancoC. (2019). Cannabis use disorders among adults in the United States during a time of increasing use of cannabis. Drug and Alcohol Dependence, 204, Article 107468.
19.
CookC.HeathF.ThompsonR. L. (2000). A meta-analysis of response rates in web-or internet-based surveys. Educational and Psychological Measurement, 60(6), 821–836.
20.
CorteseS. (2020, Sep10). Pharmacologic treatment of attention deficit-hyperactivity disorder. New England Journal of Medicine, 383(11), 1050–1056. https://doi.org/10.1056/NEJMra1917069
21.
CorteseS.AdamoN.Del GiovaneC.Mohr-JensenC.HayesA. J.CarucciS.AtkinsonL. Z.TessariL.BanaschewskiT.CoghillD.HollisC.SimonoffE.ZuddasA.BarbuiC.PurgatoM.SteinhausenH. C.ShokranehF.XiaJ.CiprianiA. (2018). Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: A systematic review and network meta-analysis. Lancet Psychiatry, 5(9), 727–738. https://doi.org/10.1016/s2215-0366(18)30269-4
22.
CranfordJ. A.ArnedtJ. T.ConroyD. A.BohnertK. M.BourqueC.BlowF. C.IlgenM. (2017). Prevalence and correlates of sleep-related problems in adults receiving medical cannabis for chronic pain. Drug and Alcohol Dependence, 180, 227–233. https://doi.org/10.1016/j.drugalcdep.2017.08.017
23.
CurranV. H.BrignellC.FletcherS.MiddletonP.HenryJ. (2002). Cognitive and subjective dose-response effects of acute oral Δ 9-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology, 164, 61–70.
24.
CuttlerC.SpradlinA.ClevelandM. J.CraftR. M. (2020). Short-and long-term effects of cannabis on headache and migraine. The Journal of Pain, 21(5–6), 722–730.
25.
CuttlerC.SpradlinA.McLaughlinR. J. (2018). A naturalistic examination of the perceived effects of cannabis on negative affect. Journal of Affective Disorders, 235, 198–205.
26.
DoremusJ. M.StithS. S.VigilJ. M. (2019). Using recreational cannabis to treat insomnia: Evidence from over-the-counter sleep aid sales in Colorado. Complementary Therapies in Medicine, 47, Article 102207.
27.
Drug Enforcement Agency (DEA) and IQVIA Government Solutions, Inc. (2023). Stimulant prescription trends in the United States from 2012-2022. Administration DEA.
28.
FosnachtK.SarrafS.HoweE.PeckL.K. (2017). How important are high response rates for college surveys?The Review of Higher Education, 40, 245–265.
29.
FranciscoA. P.LethbridgeG.PattersonB.Goldman BergmannC.Van AmeringenM. (2023). Cannabis use in attention – deficit/hyperactivity disorder (ADHD): A scoping review. Journal of Psychiatric Research, 157, 239–256. https://doi.org/10.1016/j.jpsychires.2022.11.029
30.
GinsbergL.KaticA.AdeyiB.DirksB.BabcockT.LasserR.SchecknerB.AdlerL. A. (2011). Long-term treatment outcomes with lisdexamfetamine dimesylate for adults with attention-deficit/hyperactivity disorder stratified by baseline severity. Current Medical Research and Opinion, 27(6), 1097–1107.
31.
GinsbergY.LindeforsN. (2012). Methylphenidate treatment of adult male prison inmates with attention-deficit hyperactivity disorder: Randomised double-blind placebo-controlled trial with open-label extension. The British Journal of Psychiatry, 200(1), 68–73.
32.
GujskaJ. H.SilczukA.MadejekR.SzulcA. (2023). Exploring the link between attention-deficit yyperactivity disorder and cannabis use disorders: A review. Medical Science Monitor, 29, e939749. https://doi.org/10.12659/msm.939749
33.
GukasyanN.StrainE. C. (2020). Relationship between cannabis use frequency and major depressive disorder in adolescents: Findings from the National Survey on Drug Use and Health 2012–2017. Drug and Alcohol Dependence, 208, Article 107867.
34.
HaneyM.WardA. S.ComerS. D.FoltinR. W.FischmanM. W. (1999). Abstinence symptoms following smoked marijuana in humans. Psychopharmacology, 141, 395–404.
35.
HartC. L.van GorpW.HaneyM.FoltinR. W.FischmanM. W. (2001). Effects of acute smoked marijuana on complex cognitive performance. Neuropsychopharmacology, 25(5), 757–765. https://doi.org/10.1016/s0893-133x(01)00273-1
36.
HartyS. C.PedersenS. L.GnagyE. M.PelhamW. E.JrMolinaB. S. (2015). ADHD and marijuana-use expectancies in young adulthood. Substance Use and Misuse, 50(11), 1470–1478.
37.
HasinD. S.ShmulewitzD.SarvetA. L. (2019). Time trends in US cannabis use and cannabis use disorders overall and by sociodemographic subgroups: A narrative review and new findings. American Journal of Drug and Alcohol Abuse, 45(6), 623–643. https://doi.org/10.1080/00952990.2019.1569668
38.
HasinD.WalshC. (2021). Cannabis Use, cannabis use disorder, and comorbid psychiatric illness: A narrative review. Journal of Clinical Medicine, 10(1), 15. https://www.mdpi.com/2077-0383/10/1/15
39.
HindochaC.FreemanT.XiaJ.ShabanN. D.CurranH. V. (2017). Acute memory and psychotomimetic effects of cannabis and tobacco both ‘joint’and individually: A placebo-controlled trial. Psychological Medicine, 47(15), 2708–2719.
40.
JainU.HechtmanL.QuinnD.TurgayA.YaremkoJ.MutchC. (2006). Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA): Canadian ADHD practice guidelines. CADDRA.
41.
KatzmanM. A.BilkeyT. S.ChokkaP. R.FalluA.KlassenL. J. (2017). Adult ADHD and comorbid disorders: Clinical implications of a dimensional approach. BMC Psychiatry, 17(1), 302. https://doi.org/10.1186/s12888-017-1463-3
42.
KesslerR. C.AdlerL.AmesM.DemlerO.FaraoneS.HiripiE.HowesM. J.JinR.SecnikK.SpencerT. (2005). The World Health Organization adult ADHD Self-Report Scale (ASRS): A short screening scale for use in the general population. Psychological Medicine, 35(2), 245–256.
43.
KesslerR. C.AdlerL.BarkleyR.BiedermanJ.ConnersC. K.DemlerO.FaraoneS. V.GreenhillL. L.HowesM. J.SecnikK.SpencerT.UstunT. B.WaltersE. E.ZaslavskyA. M. (2006). The prevalence and correlates of adult ADHD in the United States: Results from the National Comorbidity Survey Replication. American Journal of Psychiatry, 163(4), 716–723. https://doi.org/10.1176/ajp.2006.163.4.716
44.
KleinR. G.MannuzzaS.OlazagastiM. A. R.RoizenE.HutchisonJ. A.LashuaE. C.CastellanosF. X. (2012). Clinical and functional outcome of childhood attention-deficit/hyperactivity disorder 33 years later. Archives of General Psychiatry, 69(12), 1295–1303. https://doi.org/10.1001/archgenpsychiatry.2012.271
45.
LaFranceE. M.StueberA.GlodoskyN. C.MauzayD.CuttlerC. (2020). Overbaked: Assessing and predicting acute adverse reactions to cannabis. Journal of Cannabis Research, 2, 1–10.
46.
LandesS. D.LondonA. S. (2021). Self-reported ADHD and adult health in the United States. Journal of Attention Disorders, 25(1), 3–13. https://doi.org/10.1177/1087054718757648
47.
LeeS. S.HumphreysK. L.FloryK.LiuR.GlassK. (2011). Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: A meta-analytic review. Clinical Psychology Review, 31(3), 328–341.
48.
LeungJ.ChanG. C. K.HidesL.HallW. D. (2020). What is the prevalence and risk of cannabis use disorders among people who use cannabis? A systematic review and meta-analysis. Addictive Behaviors, 109, Article 106479. https://doi.org/10.1016/j.addbeh.2020.106479
49.
LoflinM.EarleywineM.De LeoJ.HobkirkA. (2014). Subtypes of attention deficit-hyperactivity disorder (ADHD) and cannabis use. Substance Use and Misuse, 49(4), 427–434.
50.
LondonA. S.LandesS. D. (2016). Attention deficit hyperactivity disorder and adult mortality. Preventive Medicine, 90, 8–10.
51.
LondonA. S.LandesS. D. (2021). Cohort change in the prevalence of ADHD among US adults: Evidence of a gender-specific historical period effect. Journal of Attention Disorders, 25(6), 771–782.
52.
ManfredaK. L.BosnjakM.BerzelakJ.HaasI.VehovarV. (2008). Web surveys versus other survey modes: A meta-analysis comparing response rates. International Journal of Market Research, 50(1), 79–104.
53.
MarchantB. K.ReimherrF. W.HallsC.WilliamsE. D.StrongR. E. (2010). OROS methylphenidate in the treatment of adults with ADHD: A 6-month, open-label, follow-up study. Annals of Clinical Psychiatry, 22(3), 196–204.
54.
McCabeS. E.SchulenbergJ. E.WilensT. E.SchepisT. S.McCabeV. V.VelizP. T. (2023). Prescription stimulant medical and nonmedical use among US secondary school students, 2005 to 2020. JAMA Network Open, 6(4), e238707. https://doi.org/10.1001/jamanetworkopen.2023.8707
55.
MitchellJ. T.SweitzerM. M.TunnoA. M.KollinsS. H.McClernonF. J. (2016). “I use weed for my ADHD”: A qualitative analysis of online forum discussions on cannabis use and ADHD. PloS ONE, 11(5), e0156614. https://doi.org/10.1371/journal.pone.0156614
56.
MitchellJ. T.WeisnerT. S.JensenP. S.MurrayD. W.MolinaB. S. G.ArnoldL. E.HechtmanL.SwansonJ. M.HinshawS. P.VictorE. C.KollinsS. H.WellsK. C.BelendiukK. A.BlondeA.NguyenC.AmbrizL.NguyenJ. L. (2018). How substance users with ADHD perceive the relationship between substance use and emotional functioning. Journal of Attention Disorders, 22(9_suppl), 49S–60S.
57.
NotzonD. P.PavlicovaM.GlassA.MarianiJ. J.MahonyA. L.BrooksD. J.LevinF. R. (2020). ADHD is highly prevalent in patients seeking treatment for cannabis use disorders. Journal of Attention Disorders, 24(11), 1487–1492.
58.
OlfsonM.BlancoC.WangS.GreenhillL. L. (2013). Trends in office-based treatment of adults with stimulants in the United States. Journal of Clinical Psychiatry, 74(1), 43–50. https://doi.org/10.4088/JCP.12m07975
59.
RamaekersJ. G.KauertG.TheunissenE.ToennesS. W.MoellerM. (2009). Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. Journal of Psychopharmacology, 23(3), 266–277.
60.
RyanJ. E.FruchtmanM.Sparr-JaswaA.KnehansA.WorsterB. (2024). Attention deficit hyperactivity disorder, cannabis use, and the endocannabinoid System: A scoping review. Developmental Psychobiology, 66(7), e22540. https://doi.org/10.1002/dev.22540
61.
SharpeL.SinclairJ.KramerA.de ManincorM.SarrisJ. (2020). Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties. Journal of Translational Medicine, 18, 1–21.
62.
SlabaughS. L.ShahM.ZackM.HappeL.CordierT.HavensE.DavidsonE.MiaoM.PrewittT.JiaH. (2017). Leveraging Health-Related Quality of Life in population health management: The case for Healthy Days. Population Health Management, 20(1), 13–22. https://doi.org/10.1089/pop.2015.0162
63.
SobanskiE.BrüggemannD.AlmB.KernS.DeschnerM.SchubertT.PhilipsenA.RietschelM. (2007). Psychiatric comorbidity and functional impairment in a clinically referred sample of adults with attention-deficit/hyperactivity disorder (ADHD). European Archives of Psychiatry and Clinical Neuroscience, 257(7), 371–377. https://doi.org/10.1007/s00406-007-0712-8
64.
StueberA.CuttlerC. (2022). Self-reported effects of cannabis on ADHD symptoms, ADHD medication side effects, and ADHD-related executive dysfunction. Journal of Attention Disorders, 26(6), 942–955. https://doi.org/10.1177/10870547211050949
65.
Substance Abuse and Mental Health Services Administration (SAMSHA). (2021). 2020 National Survey on Drug Use and Health (NSDUH): Methodological summary and definitions. Rockville, MD.
66.
TorgersenT.GjervanB.RasmussenK.VaalerA.NordahlH. M. (2013). Prevalence of comorbid substance use disorder during long-term central stimulant treatment in adult ADHD. Atten Defic Hyperact Disord, 5(1), 59–67. https://doi.org/10.1007/s12402-012-0094-2
67.
UritsI.CharipovaK.GressK.LiN.BergerA. A.CornettE. M.KassemH.NgoA. L.KayeA. D.ViswanathO. (2021). Adverse effects of recreational and medical cannabis. Psychopharmacology Bulletin, 51(1), 94–109.
68.
WeislerR. H.BiedermanJ.SpencerT. J.WilensT. E. (2005). Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD. CNS Spectrums, 10(S20), 35–43.
69.
WilensT. E. (2006). Attention deficit hyperactivity disorder and substance use disorders. The American Journal of Psychiatry, 163(12), 2059–2063. https://doi.org/https://dx-doi-org.web.bisu.edu.cn/10.1176/appi.ajp.163.12.2059
70.
WillcuttE. G. (2012). The prevalence of DSM-IV attention-deficit/hyperactivity disorder: A meta-analytic review. Neurotherapeutics, 9(3), 490–499. https://doi.org/10.1007/s13311-012-0135-8
71.
ZahranH. S.KobauR.MoriartyD. G.ZackM. M.HoltJ.DonehooR. (2005). Health-related quality of life surveillance—United States, 1993–2002. Morbidity and Mortality Weekly Report: Surveillance Summaries, 54(4), 1–35.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
